Refine your search
3,205 results found
Herbert Smith Freehills LLP | China | 25 May 2022
China’s first decision in a case initiated under its patent linkage system
China has recently seen the first decision in a case initiated under its patent linkage system. Under this system, when a generic drug company files…
Zhong Lun Law Firm | China | 19 May 2022
我国现行药品专利链接制度存在的问题及完善建议（下）
2021年6月1日实施的《专利法》第76条正式规定了药品专利链接制度，随后国家药品监督管理局、国家知识产权局、最高人民法院陆续出台…
Zhong Lun Law Firm | China | 18 May 2022
我国现行药品专利链接制度存在的问题及完善建议（上）
2021年6月1日实施的《专利法》第76条正式规定了药品专利链接制度，随后国家药品监督管理局、国家知识产权局、最高人民法院陆续出台…
Saint Island International Patent & Law Offices | Taiwan | 24 Apr 2022
Medical Use Claims and Indications Specified on Generic Drug Approvals
In an attempt to resolve disputes on patent invalidity and infringement among brand drug companies and generic drug companies, a patent linkage…
Lexology PRO | Asia-Pacific, Australia | 23 Mar 2022
ACCC refuses to approve pharma agreement in rare patent settlement request
Australia’s antitrust authority has voiced its concerns about a proposed patent dispute settlement and licensing agreement between Celgene and two drugmakers, warning that it could distort competition between generic manufacturers.
Pearl Cohen Zedek Latzer Baratz | Israel | 25 Oct 2021
Loophole to enhance generics' ability to launch at risk during patent term extension protection period
The Israeli Ministry of Justice has proposed changes to Israel's patent term extension laws that significantly enhance generics' ability to launch at risk. Although the proposal ostensibly offers Israeli generics the same benefits afforded to European generics, the proposal does not include the safeguards found in the European regulations. If the proposal is ratified, innovators will need to......
Lexology PRO | United Kingdom | 29 Jul 2021
CMA doles out £100 million in fines for excessive pricing of thyroid drug
The UK’s Competition and Markets Authority has hit Advanz Pharma and its two former owners with more than £100 million in fines for overcharging the country’s national health service for thyroid medication liothyronine over an eight-year period.
Wanhuida Intellectual Property | China | 26 Jul 2021
China issues implementation measures on pharmaceutical patent linkage system
The National Medical Products Administration and the China National Intellectual Property Administration recently jointly released the Measures for the Implementation of Early Resolution Mechanism for Pharmaceutical Patent Disputes (for Trial Implementation) (the measures), ironing out the operational details of the pharmaceutical patent linkage system. This article provides a brief......
Herbert Smith Freehills LLP | Australia | 29 Apr 2020
Commonwealth fails in its claim for compensation for PBS expenditure
Justice Nicholas’ long-awaited decision in Commonwealth v Sanofi is an Australian first. Of the 4 cases in Australia in which the Commonwealth has…
Peksung Intellectual Property Ltd | China | 20 Apr 2020
中国仿制药的发展现状分析
仿制药是指与原研药在剂量、安全性、效力、质量、药效以及适应症上均相同的一种仿制药品。现代仿制药起源于1984…
